CD4 T CELL ASSESSMENTS IN EVALUATION OF HIV THERAPEUTICS - Flow Cytometry in Drug Discovery and Development - page 175

TABLE 8.3 Indications for Initiating Antiretroviral Therapy for the ChronicallyHIV-1
Infected Patient a

Clinical Condition and/or CD4 Count Recommendations

History of AIDS-defining illness (AI)
CD4 count < 200 cells/mm 3 (AI)
CD4 count 200-350 cells/mm 3 (AII)
Pregnant women b (AI)
Persons with HIV-associated
nephropathy (AI)Persons coinfected
with hepatitis B virus (HBV), when
HBV treatment is indicated
(treatment with fully suppressive
antiviral drugs active against both
HIV and HBV is recommended.)
(BIII)

Antiretroviral therapy should be
initiated

Patients with CD4 count > 350 cells/
mm 3 who do not meet any of the
specific conditions listed above

The optimal time to initiate therapy in
asymptomatic patients with CD4
count > 350 cells/mm 3 is not well
defined. Patient scenarios and
comorbidities should be taken into
consideration

a Updated December 1, 2007.
b Panel onAntiretroviral Guidelines forAdults andAdolescents. Guidelines for theuse of antiretroviral agents
in HIV-1-infected adults and adolescents, Department of Health and Human Services, November 3, 2008;
1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed Jun.
16, 2008, p. 7, Table 5a.

TABLE 8.4 WHO Clinical Staging of HIV/AIDS for Adults and Adolescents

Primary HIV infection
Asymptomatic
Acute retroviral syndrome
Clinical stage 1
Asymptomatic
Persistent generalized lymphadenopathy
Clinical stage 2
Moderate unexplained weight loss ( < 10% of presumed or measured body weight)
Recurrent respiratory infections (sinusitis, tonsillitis, otitis media, and pharyngitis)
Herpes zoster
Angular cheilitis
Recurrent oral ulceration
Papular pruritic eruptions
Seborrheic dermatitis
Fungal nail infections

(continued)